Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021
Dispatch

Bordetella hinzii Pneumonia and Bacteremia in a Patient with SARS-CoV-2 Infection

Michele Maison-Fomotar and Geetha SivasubramanianComments to Author 
Author affiliation: University of California, San Francisco, Fresno, California, USA

Main Article

Table 2

Characteristics of previously reported Bordetella hinzii infections*

Ref.† Type of infection Age, y Underlying conditions Animal exposure Antimicrobial drugs Patient outcome
(5)
 Bacteremia
 24
 HIV/AIDS
 None
 Ceftazidime
 Recovered
(4)
 Pneumonia
 NA
 HIV/AIDS
 None
 NA
 NA
(6)
 Bacteremia and cholangitis
 69
 None
 None
 Ticarcillin/sulbactam, ciprofloxacin
 Died
(7)
 Cholangitis
 29
 Primary sclerosing cholangitis, liver transplant recipient
 None
 Meropenem
 Died
(8)
 Bacteremia
 79
 Myelodysplastic syndrome
 None
 Ceftazidime
 Recovered
(9)
 Bacteremia
 36
 EBV associated diffuse large cell lymphoma
 None
 Meropenem
 Died
(10)
 Pneumonia
 43
 AML, transplant, diabetes bronchiectasis
 Poultry
 Piperacillin/tazobactam,
ciprofloxacin
 Recovered
(10)
 Pneumonia
 74
 Laryngeal cancer, prostate cancer, diabetes, COPD
 None
 Piperacillin/tazobactam
 Recovered
(11)
 Urinary tract infection
 55
 None
 Possible poultry
 Trimethoprim/
sulfamethoxazole
 Recovered
(11)
 Liver abscess
 58
 Hypothyroidism, cholecystectomy
 None
 None
 Recovered
(12)
 Bacteremia and infective endocarditis
 79
 Aortic valve replacement, diabetes, cirrhosis, colon cancer, kidney disease
 None
 Meropenem
 Recovered
(13)
 Bacteremia and infective endocarditis
 53
 Ulcerative colitis
 None
 Ceftazidime
 Recovered
(14)
 Soft tissue abscess
 63
 None
 None
 Sitafloxacin
 Recovered
(15)
 Pancreatic abscess
 42
 Alcoholic liver disease
 None
 Tigecycline
 Recovered
(16)
 Urinary tract infection
 37
 Chronic alcohol use
 None
 Trimethoprim/sulfamethoxazole
 Recovered
(17) Pneumonia 67 Diabetes mellitus None Cefmetazole Recovered

*AML, Acute myeloid leukemia; COPD, chronic obstructive pulmonary disease; EBV, Epstein-Barr virus; NA, not available; ref., reference. †References 16,17 in Appendix.

Main Article

References
  1. WHO. COVID-19 dashboard [cited 2021 Jun 28]. https://covid19.who.int
  2. Chen  X, Liao  B, Cheng  L, Peng  X, Xu  X, Li  Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020;104:7777–85. DOIPubMedGoogle Scholar
  3. Mattoo  S, Cherry  JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18:326–82. DOIPubMedGoogle Scholar
  4. Gadea  I, Cuenca-Estrella  M, Benito  N, Blanco  A, Fernández-Guerrero  ML, Valero-Guillén  PL, et al. Bordetella hinzii, a “new” opportunistic pathogen to think about. J Infect. 2000;40:298–9. DOIPubMedGoogle Scholar
  5. Cookson  BT, Vandamme  P, Carlson  LC, Larson  AM, Sheffield  JV, Kersters  K, et al. Bacteremia caused by a novel Bordetella species, “B. hinzii”. J Clin Microbiol. 1994;32:2569–71. DOIPubMedGoogle Scholar
  6. Kattar  MM, Chavez  JF, Limaye  AP, Rassoulian-Barrett  SL, Yarfitz  SL, Carlson  LC, et al. Application of 16S rRNA gene sequencing to identify Bordetella hinzii as the causative agent of fatal septicemia. J Clin Microbiol. 2000;38:789–94. DOIPubMedGoogle Scholar
  7. Arvand  M, Feldhues  R, Mieth  M, Kraus  T, Vandamme  P. Chronic cholangitis caused by Bordetella hinzii in a liver transplant recipient. J Clin Microbiol. 2004;42:2335–7. DOIPubMedGoogle Scholar
  8. Fry  NK, Duncan  J, Edwards  MT, Tilley  RE, Chitnavis  D, Harman  R, et al. A UK clinical isolate of Bordetella hinzii from a patient with myelodysplastic syndrome. J Med Microbiol. 2007;56:1700–3. DOIPubMedGoogle Scholar
  9. Hristov  AC, Auwaerter  PG, Romagnoli  M, Carroll  KC. Bordetella hinzii septicemia in association with Epstein-Barr virus viremia and an Epstein-Barr virus-associated diffuse large B-cell lymphoma. Diagn Microbiol Infect Dis. 2008;61:484–6. DOIPubMedGoogle Scholar
  10. Fabre  A, Dupin  C, Bénézit  F, Goret  J, Piau  C, Jouneau  S, et al. Opportunistic pulmonary Bordetella hinzii infection after avian exposure. Emerg Infect Dis. 2015;21:2122–6. DOIPubMedGoogle Scholar
  11. Almuzara  M, Barberis  C, Traglia  GM, Sly  G, Procopio  A, Vilches  V, et al. Isolation of Bordetella species from unusual infection sites. JMM Case Rep. 2015;2:e000029. DOIGoogle Scholar
  12. González  MM, Romano  MPC, de Guzmán García Monge  MT, Martín  BB, García  AS. Bordetella hinzii endocarditis, a clinical case not previously described. Eur J Case Rep Intern Med. 2019;6:000994.PubMedGoogle Scholar
  13. Zohourian  H, Sorokin  AV, Ladna  JM, Mushtaq  F. Bordetella hinzii: an unexpected pathogen in native valve endocarditis. Can J Cardiol. 2019;35:1604.e17–9. DOIPubMedGoogle Scholar
  14. Negishi  T, Matsumoto  T, Shinagawa  J, Kasuga  E, Horiuchi  K, Natori  T, et al. A case of cervical subcutaneous abscess due to Bordetella hinzii. Diagn Microbiol Infect Dis. 2019;95:114865. DOIPubMedGoogle Scholar
  15. Kampmeier  S, Rennebaum  F, Schmidt  H, Riegel  A, Herrmann  M, Schaumburg  F. Peripancreatic abscess supported by Bordetella hinzii. New Microbes New Infect. 2020;34:100650. DOIPubMedGoogle Scholar

Main Article

Page created: August 05, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external